Bristol “Dear Doctor” Letter: Abilify Shows No “Signal” For Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
An “exhaustive review” of the aripiprazole database revealed “no increased signal for diabetes,” Bristol says in health care professionals letter explaining the new class warning for atypical antipsychotics.
You may also be interested in...
Bristol/Otsuka's Abilify Adds Acute Bipolar Mania Indication
FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.
Bristol/Otsuka's Abilify Adds Acute Bipolar Mania Indication
FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.
Geodon Labeling Changes Still Under Discussion, Pfizer Says
Pfizer is continuing to discuss new safety labeling for the antipsychotic Geodon (ziprasidone) with FDA, the company said in its April 20 earnings report